Eli Lilly and Company $LLY Holdings Lifted by SevenBridge Financial Group LLC

SevenBridge Financial Group LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 16.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,354 shares of the company’s stock after acquiring an additional 1,162 shares during the period. Eli Lilly and Company makes up about 1.1% of SevenBridge Financial Group LLC’s investment portfolio, making the stock its 21st largest position. SevenBridge Financial Group LLC’s holdings in Eli Lilly and Company were worth $6,374,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Laurel Wealth Advisors LLC boosted its position in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $8,827,714,000. Capital Research Global Investors raised its holdings in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Eli Lilly and Company by 47.6% during the third quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company’s stock valued at $1,761,772,000 after purchasing an additional 744,868 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will invest $3 billion in China over the next decade to expand supply‑chain and local manufacturing capacity — including production for its oral GLP‑1 orforglipron — which supports global supply resilience and access to China’s large diabetes/obesity market. Eli Lilly to invest $3 billion in China over next decade
• Positive Sentiment: Lilly has filed for approval of its new GLP‑1 treatment in China, a step that could accelerate launches of both injectable and oral therapies in a critical growth market. Eli Lilly plans $3 billion China investment, files for approval of new GLP-1 treatment
• Positive Sentiment: Clinical/program updates: Lilly reported completion of a Phase 1 study for a China program (LY3985863) and continues strong head‑to‑head data for oral orforglipron versus oral semaglutide — supporting market potential for a lower‑cost, high‑volume oral GLP‑1. Eli Lilly Advances New LY3985863 Program With Completion of Phase 1 Study in China
• Positive Sentiment: Access initiatives: Lilly launched Employer Connect to push employer coverage of obesity drugs (discounted pricing and PBM bypass). If widely adopted, this could materially expand payer coverage and volume (potential 2027 upside), though it may compress per‑unit margins. Eli Lilly and Company (LLY) Announces the Launch of its Employer Connect Platform
• Neutral Sentiment: Partnerships and R&D footprint expansion — Lilly is building a Gateway Labs hub with Samsung Biologics in South Korea and pledging regional investments, which support long‑term R&D sourcing and local talent pipelines but won’t drive immediate revenue. Eli Lilly Taps Samsung Biologics To Grow Korean Biotech And Long Term Value
• Neutral Sentiment: Industry movement: a former Lilly communications chief joined Hims & Hers — notable for competitive dynamics around obesity drugs and messaging but not a direct LLY revenue driver. Hims & Hers Hires Ex-Eli Lilly Communications Chief Amid Obesity Drug Strategy Shift
• Negative Sentiment: Payer/regulatory pressure: Lilly warned some Medicare beneficiaries could still face out‑of‑pocket costs above $50 under a new CMS model because certain Part D plans may not fully meet the cap — a potential headwind for uptake and public optics. Lilly Warns Some Medicare GLP-1 Costs Could Exceed $50
• Negative Sentiment: Marketing limits in key markets: India’s regulator warned against direct or surrogate advertising of weight‑loss drugs, which could restrict promotional channels and slow commercial rollout/awareness in a fast‑growing market. India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Guggenheim raised their price objective on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Leerink Partners lifted their target price on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a report on Thursday, February 5th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 2nd. Finally, Argus upped their target price on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a report on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.59.

Eli Lilly and Company Stock Down 0.2%

Shares of NYSE:LLY opened at $999.23 on Thursday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The company has a market cap of $944.10 billion, a PE ratio of 43.54, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a 50 day simple moving average of $1,041.12 and a 200 day simple moving average of $947.08.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same quarter last year, the business posted $5.32 EPS. The company’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.